Related Experiment Video
Updated: Jun 18, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer
Xu Zhou1, Wantao Chen, Yuexing Zhang
1Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Objective:
An ErbB3-binding protein 1 (Ebp1), was shown to be a potent tumor suppressor in breast and prostate cancer cells. We hypothesized that the inhibitory properties of the Ebp1 gene could be beneficial if ectopically expressed in oral squamous cell carcinoma (OSCC) cells.
Methods:
One OSCC cell line Tca8113 was stably transfected with the complete Ebp1 cDNA or the vector control pcDNA3.1. The inhibitory effect was evaluated using in vitro proliferation assay, cell cycle distribution and anchorage-independent growth in soft agar as well as in vivo tumorigenicity.
Results:
Stable gene transfer was verified by Western Blot analysis and reverse transcription RT-PCR. Following transfection of Ebp1, a significant reduction in cell proliferation and anchorage-independent growth in soft agar were observed. Ectopic expression of Ebp1 led to a change in cell cycle profile and most importantly, a strong decrease in tumorigenicity of human OSCC cell line in a xenograft mouse model.
Conclusions:
Ectopic expression of Ebp1 mediates multiple antitumor activities against OSCC, suggesting a potential of Ebp1-based novel therapy for clinical OSCC treatment.
Insights
ErbB3-binding protein 1 (Ebp1) suppressed oral squamous cell carcinoma (OSCC) growth. Ectopic Ebp1 expression reduced OSCC cell proliferation, soft agar growth, and in vivo tumorigenicity, indicating potential for novel OSCC therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- ErbB3-binding protein 1 (Ebp1) exhibits tumor suppressor activity in breast and prostate cancers.
- Oral squamous cell carcinoma (OSCC) is a significant global health concern requiring novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential of Ebp1 as a therapeutic agent against OSCC.
- To evaluate the effects of ectopic Ebp1 expression on OSCC cell behavior and tumorigenicity.
Main Methods:
- Stable transfection of Tca8113 OSCC cells with Ebp1 cDNA or vector control.
- Assessment of proliferation, cell cycle, anchorage-independent growth, and in vivo tumorigenicity.
- Verification of gene transfer using Western Blot and RT-PCR.
Main Results:
- Ectopic Ebp1 expression significantly reduced OSCC cell proliferation and anchorage-independent growth.
- Ebp1 transfection altered cell cycle distribution.
- In vivo studies demonstrated a marked decrease in OSCC xenograft tumor formation.
Conclusions:
- Ectopic Ebp1 expression confers potent antitumor activities against OSCC.
- Ebp1 holds promise as a novel therapeutic target for clinical OSCC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle